The technology will enable new products for a leading segment of RB’s product portfolio. Detailed financial terms were not disclosed.
| |
| [03-January-2018] |
| LENEXA, Kan., Jan. 3, 2018 /PRNewswire/ -- Orbis Biosciences, Inc. announced today that it has entered into an exclusive global license agreement leveraging its Precision Particle Fabrication® technology. Reckitt Benckiser (RB), world leading Consumer Healthcare company, and Orbis have entered into an exclusive cooperation agreement to develop and commercialize novel technologies in the field of consumer healthcare. The technology will enable new products for a leading segment of RB’s product portfolio. Detailed financial terms were not disclosed. “We are proud to be partnering with one of the largest consumer products companies in the world to create differentiated products for their portfolio. The ability to add novel products to their extensive offering will provide patients the choice and flexibility they need to ease administration challenges,” said Maria Flynn, CEO and President of Orbis Biosciences. “We are very excited to partner with the Orbis Biosciences talented team to strengthen further our innovation pipeline in strategic areas of our leading consumer health relief portfolio. At RB, we believe that vibrant partnerships are critical in delivering RB purpose of innovative solutions for Healthier Lives and Happier Homes,” said Laurent Faracci, Executive VP Category Development for RB Health. Highlights:
About Orbis Biosciences - Orbis is a pharmaceutical manufacturing technology company focused on licensing its technology to companies to optimize their product portfolios. Orbis develops customized formulations and intellectual property for pharmaceutical product manufacture, leveraging Orbis’ novel Precision Particle Fabrication® technology platforms: Optimµm® precision encapsulation for oral delivery, StratµmTM precision encapsulation for injectable delivery, and the Unisun® platform for enabling sustained-release otic therapies. Providing industry innovation, the company offers cost-effective reformulation pathways to improve pharmaceutical products for improved health outcomes. For more information about Orbis, visit orbisbio.com. About Reckitt Benckiser - RB is the global leading consumer health and hygiene company. Driven by a purpose of providing innovative solutions for healthier lives and happier homes, RB has operations in over 60 countries. From the foundations of wellness and infant nutrition, to the fundamentals of a hygienic home, its global brands help people live healthier, happier lives. RB has world leading Powerbrands which include household names such as Enfamil, Nutramigen, Nurofen, Strepsils, Gaviscon, Mucinex, Durex, Scholl, Clearasil, Lysol, Dettol, Veet, Harpic, Cillit Bang, Mortein, Finish, Vanish, Calgon, Woolite and Air Wick.
View original content with multimedia:http://www.prnewswire.com/news-releases/orbis-biosciences-announces-licensing-agreement-with-reckitt-benckiser-300576488.html SOURCE Orbis Biosciences |
